MARKET

SNTI

SNTI

Senti Bioscience
NASDAQ
3.210
+0.110
+3.55%
After Hours: 3.220 +0.01 +0.31% 19:50 05/14 EDT
OPEN
3.320
PREV CLOSE
3.100
HIGH
3.329
LOW
3.081
VOLUME
24.06K
TURNOVER
--
52 WEEK HIGH
16.94
52 WEEK LOW
1.520
MARKET CAP
83.72M
P/E (TTM)
-0.3117
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SNTI last week (0505-0509)?
Weekly Report · 2d ago
Senti Bio releases mechanism of action video for SENTI-202
TipRanks · 6d ago
Senti Biosciences Announces Release Of Its New Animated Video For Its Lead Asset In Development Senti-202 Cell Therapy Product Candidate Designed To Selectively Target And Eliminate CD33 And/Or FLT3-Expressing Hematologic Malignancies
Benzinga · 6d ago
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
Barchart · 6d ago
Senti Biosciences GAAP EPS of -$1.41
Seeking Alpha · 05/07 13:50
Senti Biosciences Reports Promising Q1 2025 Results
TipRanks · 05/07 04:24
*Senti Biosciences 1Q Loss/Shr $1.41 >SNTI
Dow Jones · 05/06 20:48
BRIEF-Senti Biosciences Q1 Net Income USD -14.112 Million
Reuters · 05/06 20:35
More
About SNTI
More
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
Recently
Symbol
Price
%Change

Webull offers Senti Biosciences Inc stock information, including NASDAQ: SNTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNTI stock methods without spending real money on the virtual paper trading platform.